Identification and Isolation of Oligopotent and Lineage-committed Myeloid Progenitors from Mouse Bone Marrow
July 29th, 2018
8.5K views
We demonstrate how to identify and isolate 6 subsets of myeloid progenitors from murine bone marrow using a combination of magnetic and fluorescence sorting (MACS and FACS). This protocol can be used for in vitro culture assays (methylcellulose or liquid cultures), in vivo adoptive transfer experiments, and RNA/protein analyses.
Overview
This article demonstrates a method for identifying and isolating six subsets of myeloid progenitors from murine bone marrow using magnetic and fluorescence sorting techniques. The protocol is applicable for various assays, including in vitro culture and RNA/protein analyses.
Key Study Components
Area of Science
- Hematology
- Immunology
- Cell Biology
Background
- Myeloid cells play a crucial role in the immune response.
- Understanding myeloid progenitor subsets is essential for studying their functions.
- Previous methods lacked precision in identifying these subsets.
- This study introduces a refined technique for better identification.
Purpose of Study
- To provide a reliable method for isolating myeloid progenitor subsets.
- To enhance the understanding of myeloid cell production and function.
- To facilitate further research in hematology and immunology.
Methods Used
- Magnetic-activated cell sorting (MACS) for cell enrichment.
- Fluorescence-activated cell sorting (FACS) for precise identification.
- In vitro culture assays using methylcellulose or liquid cultures.
- RNA and protein analyses for functional studies.
Main Results
- Successful isolation of six distinct myeloid progenitor subsets.
- Improved accuracy in identifying progenitor cells compared to previous methods.
- Protocol applicable for various downstream applications.
- Potential to advance research in myeloid cell biology.
Conclusions
- The method provides a significant advancement in myeloid progenitor research.
- It opens new avenues for studying myeloid cell functions.
- Researchers can utilize this protocol for diverse experimental applications.
Frequently Asked Questions
What are myeloid progenitors?
Myeloid progenitors are precursor cells that give rise to various types of myeloid cells, including neutrophils and monocytes.
How does MACS work?
MACS uses magnetic beads coated with antibodies to isolate specific cell types from a mixture based on their surface markers.
What is the significance of isolating myeloid progenitor subsets?
Isolating these subsets allows researchers to study their specific roles and functions in the immune system.
Can this method be applied to human samples?
While this protocol is designed for murine models, similar techniques can be adapted for human samples with appropriate modifications.
What downstream applications can this protocol support?
The protocol can support in vitro culture assays, RNA/protein analyses, and in vivo adoptive transfer experiments.
Is prior experience required to use this method?
Some experience with cell sorting techniques and basic laboratory skills is recommended for optimal results.
Executive Industry Relevance
Precise identification of myeloid progenitor subsets enables mechanistic de-risking in hematology and immunology target validation. Improved resolution of oligopotent and lineage-committed populations supports predictive confidence in differentiation pathways. This approach enhances portfolio triage by reducing biological ambiguity in preclinical models of myeloid disorders.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses in neutrophil, monocyte, and dendritic cell differentiation pathways.
- Operational Value: Provides biologically de-risked progenitor subsets for functional target validation.
- Predictive Value: Supports lead identification by clarifying lineage commitment and oligopotency in myeloid progenitors.
Screening & Assay Development
- Assay Readiness: Generates standardized, reproducible progenitor populations for downstream compound screening.
- Quantitative Output: Permits progenitor quantification and isolation for in vitro and in vivo functional assays.
- Platform Reuse: Enables scalable preparation of validated myeloid systems for assay standardization across projects.
Translational & Preclinical Research
- Disease Relevance: Supports study of leukemic transformation mechanisms and immune responses to pathogen exposure.
- Translational Continuity: Bridges discovery through preclinical validation of myeloid progenitor function.
- Risk-Adjusted Decisions: Informs advancement decisions by linking progenitor subsets to myeloid cell production outcomes.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from progenitor enrichment to functional validation, supporting hypothesis testing and pathway clarification in myeloid biology.
- Discovery Biology: Supports hypothesis testing and biological de-risking of myeloid differentiation pathways.
- Screening: Delivers assay-ready progenitor subsets with high purity for reliable compound evaluation.
- Analytics: Enables quantitative measurements of progenitor frequency and functional output for comparative condition analysis.
- Translational Research: Connects subset isolation to preclinical continuity in myeloid cell production studies.
- Enterprise Reuse: Establishes a reusable capability for isolating oligopotent and lineage-committed myeloid progenitors across hematology and immunology programs.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in myeloid lineage commitment and reduced mechanistic ambiguity in progenitor function.
- Operational Value: Standardization, reproducibility, and scalability of progenitor isolation via MACS and FACS.
- Strategic Value: Better go/no-go decisions through improved target validation and reduced late-stage biological risk in myeloid-targeted programs.
- Portfolio Impact: Risk-adjusted prioritization based on precise progenitor subset identification and functional validation.
Implementation Considerations
- Requires expertise in multicolor flow cytometry and magnetic-activated cell sorting techniques.
- Dependent on access to FACS instrumentation and analytical infrastructure for high-resolution sorting.
- Necessitates cross-team standardization of antibody panels and gating strategies for consistent progenitor identification.
- Involves adaptation considerations when applying the protocol to different mouse strains or disease models.
- Limited by the need for careful antibody titration and fluorophore selection to ensure optimal population separation.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in myeloid progenitor studies?
Null hypothesis testing establishes statistical confidence that observed differences in myeloid progenitor subsets are not due to random variation. This supports rigorous target validation by confirming that changes in progenitor frequency or function are biologically meaningful. Such statistical rigor is essential for de-risking therapeutic hypotheses in hematology and immunology programs.
How does independent variable isolation fit the discovery pipeline for myeloid progenitor identification?
Isolating independent variables such as specific surface marker combinations enables precise identification of oligopotent and lineage-committed myeloid progenitor subsets. This reduction in heterogeneity allows researchers to attribute functional outcomes to defined progenitor populations. Such isolation is critical for building reliable discovery-stage assays and validating mechanistic models of myeloid differentiation.
What quantitative dependent variable measurements enable functional assessment of isolated myeloid progenitors?
Quantitative measurements such as progenitor yield, post-sort purity, and differentiation capacity into neutrophils, monocytes, and dendritic cells enable functional assessment. These dependent variables provide objective readouts for comparing progenitor behavior across experimental conditions. Such measurements support data-driven decisions in target validation and lead identification workflows.
Why do replication requirements matter for cross-functional collaboration in myeloid progenitor research?
Replication requirements ensure that myeloid progenitor isolation and characterization are consistent across laboratories and experimental batches. This consistency enables reliable cross-functional collaboration between discovery, preclinical, and translational teams. Standardized replication supports portfolio-wide reproducibility and reduces variability in target validation efforts.
What statistical analysis capabilities are required before implementing this myeloid progenitor isolation protocol?
Implementation requires statistical analysis capabilities to assess progenitor yield, purity, and functional output with confidence. Teams must be able to apply appropriate tests to determine significant differences in progenitor subsets across conditions. Such capabilities are essential for interpreting flow cytometry data and supporting go/no-go decisions in target validation pipelines.
